Download presentation
Presentation is loading. Please wait.
Published byJemima Foster Modified over 9 years ago
1
HEART FAILURE Jamil Mayet Consultant Cardiologist
2
Heart failure Cardiac output that is insufficient to meet the needs of the body –Myocardial dysfunction eg IHD, CM –Volume overload eg AR, MR –Obstruction eg AS, HCM –Diastolic dysfunction eg Constriction –Mechanical problems eg LV aneurysm –Rhythm disturbance eg A fib –High output eg anaemia, shunts, thyrotox
6
Heart failure - diagnosis
7
Heart failure symptoms SOBE Orthopnoea, PND Ankle swelling Anorexia, weight loss Cold peripheries Tiredness Heart failure signs Tachycardia, hypotension Raised JVP, S3 May be PSM of MR (or TR) Basal crepitations Ankle oedema Not useful to divide into right and left heart failure
8
Heart failure - diagnosis
9
ECG - normal If ECG normal very unlikely to be systolic dysfunction
10
ECG - abnormal Previous MI, LBBB, Non-specific ST/T abnormalities
11
CXR – pulmonary oedema
12
CXR – septal lines
13
Echocardiography Confirms / refutes diagnosis of systolic dysfunction Can exclude significant valvular disease Can suggest ischaemic aetiology if regional wall motion abnormality Can assess diastolic dysfunction
14
Treatment – Acute heart failure Sit up High dose oxygen Intravenous loop diuretic Venodilation eg intravenous GTN Possibly intravenous diamorphine (Venesection, dialysis) Intubation and ventilation Cardiogenic shock Severe hypotension Poor tissue perfusion - Oliguria, Confusion Mortality 80%+ Inotropes eg Dopamine, Dobutamine IABP +/- angioplasty if cardiac ischaemia
15
Chronic heart failure - Mortality
16
Heart failure - treatment Salt restriction Fluid restriction Diuretics –Usually loop diuretics –Occasionally add thiazides May lead to excessive diuresis, electrolyte imbalance Amiloride, triamtarene may prevent low K
17
Treatment – vasodilators Reduce preload / afterload –ACEI Reduce morbidity and mortality Interact with RAAS Prevent adverse remodelling post MI May precipitate renal failure Cough in 10-15% (consider AII blockers) –Nitrates and hydralazine Reduce morbidity / mortality but less than ACEI
21
Treatment - inotropes Digoxin –Reduces hospital admissions –No reduction in mortality –Stopping may precipitate deterioration All other oral positive inotropes to date have caused an increased mortality
23
Treatment – beta blockers
24
Similar degree to ACEI and additive Possibly via reduction in sympathetic activation May precipitate pulmonary oedema –Start low doses and slowly titrate up
25
Treatment – spironolactone
26
Treatment - spironolactone Probably via blockage of aldosterone May precipitate hyperkalaemia and renal failure
28
Diagnosing ischaemic heart disease 75% of white males in SOLVD were related to ischaemic heart disease75% of white males in SOLVD were related to ischaemic heart disease 50% of patients in Framingham had an ischaemic aetiology to their heart failure50% of patients in Framingham had an ischaemic aetiology to their heart failure Identification of patients who will benefit from revascularisationIdentification of patients who will benefit from revascularisation
29
Hibernating myocardium Chronic LV dysfunction does not necessarily imply dead myocardiumChronic LV dysfunction does not necessarily imply dead myocardium “Hibernating myocardium” termed by Rahimtoola in 1989“Hibernating myocardium” termed by Rahimtoola in 1989 LV systolic function improved following coronary revascularisationLV systolic function improved following coronary revascularisation Rahimtoola. Am Heart J 1989;117:211-21
30
Hibernating myocardium
31
Pacing for heart failure
32
Defibrillators for heart failure
33
Diastolic heart failure Up to a third of patients have clinical heart failure with normal LV systolic function Underlying pathophysiology relates to diastolic dysfunction Commonest underlying pathologies –Normal ageing –Hypertension –Myocardial ischaemia
34
Mechanisms of diastolic dysfunction Impaired ventricular relaxation –Energy dependent process –Susceptible to myocardial ischaemia Decreased myocardial compliance –Altered compliance mediated by collagen –Fibrosis related to activation of RAAS
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.